Empyema Thoracis (Adult)

Quick Reference

Critical Alerts

• Empyema is a surgical infection - drainage is essential alongside antibiotics; antibiotics alone are insufficient [1,2]
• Delay in drainage increases mortality - early intervention (within 3 days) improves outcomes and reduces need for surgery [3,4]
• Complicated parapneumonic effusion progresses to empyema without drainage intervention [5]
• Loculated effusions require enhanced intervention: fibrinolytics (tPA/DNase) or surgical referral [6]
• Suspect empyema in any patient with pneumonia failing to improve after 48-72 hours of appropriate antibiotics [1,2]
• pH less than 7.2 mandates drainage - do not wait for positive culture results [7]

Key Diagnostics

• CT chest with contrast - gold standard for diagnosis, staging, detecting loculations, and guiding intervention [8]
• Diagnostic thoracentesis with pleural fluid analysis in all cases [2]
• Pleural fluid criteria for empyema/complicated parapneumonic effusion: pH less than 7.2, glucose less than 3.3 mmol/L (60 mg/dL), LDH >1000 IU/L, positive Gram stain/culture, or frank pus [7,9]
• Light's criteria to distinguish exudate from transudate [10]
• Blood cultures (positive in ~20% of cases) [11]
• Inflammatory markers (CRP, procalcitonin) for monitoring treatment response [12]

Emergency Treatments

• IV antibiotics: Empiric broad-spectrum coverage including anaerobes (community-acquired) or anti-MRSA/anti-pseudomonal (nosocomial) [1,2]
• Pleural drainage: Image-guided chest tube (12-14Fr small-bore or 24-28Fr large-bore) within 24 hours of diagnosis [2,13]
• Intrapleural fibrinolytics: Alteplase (tPA) 10mg + Dornase alfa (DNase) 5mg twice daily for 3 days in loculated empyema - reduces surgical referral by 50% [6]
• Cardiothoracic surgery consultation: For loculations not responding to fibrinolytics, thick septations, organizing stage disease, or failed drainage [2,14]
• Supportive care: Supplemental oxygen, IV fluids, analgesia, nutritional support [2]

---

Definition

Empyema thoracis is defined as the presence of pus in the pleural space, representing the end-stage of a spectrum of pleural space infections. [1,2] The disease begins with simple parapneumonic effusion, progresses through complicated parapneumonic effusion, and culminates in frank empyema if untreated. The term "pleural infection" encompasses both complicated parapneumonic effusion and empyema. [2]

Early recognition and aggressive management combining antibiotics with pleural drainage are crucial, as delay beyond 3 days from diagnosis significantly increases mortality and need for surgical intervention. [3,4]

Stages of Pleural Infection

Pleural infection evolves through three distinct pathophysiological stages, each with different treatment implications: [1,2,15]

The transition between stages is variable and depends on bacterial virulence, host immune response, and timing of antibiotic therapy. [15]

Classification

Simple Parapneumonic Effusion [7,9]

• Sterile or low bacterial count
• pH >7.2
• Glucose >3.3 mmol/L (60 mg/dL)
• LDH less than 1000 IU/L
• Free-flowing on ultrasound
• Resolves with antibiotics alone - drainage not required

Complicated Parapneumonic Effusion [7,9] Requires drainage if ANY of the following:

• pH less than 7.2
• Glucose less than 3.3 mmol/L (60 mg/dL)
• LDH >1000 IU/L
• Positive Gram stain or culture
• Loculated appearance on imaging

Empyema [1,2]

• Frank pus on thoracentesis (macroscopic) OR
• Positive bacterial culture with biochemical markers of complicated parapneumonic effusion

Epidemiology

• Incidence: Empyema develops in 1-5% of patients hospitalized with community-acquired pneumonia [16]
• Annual incidence: Approximately 5-10 per 100,000 population in developed countries, increasing in recent decades [16]
• Mortality: 5-10% with appropriate treatment; 15-20% in elderly or immunocompromised patients; up to 30% if drainage delayed >7 days [3,4,11]
• Age distribution: Bimodal - peaks in children less than 5 years and adults >65 years [16]
• Gender: Male predominance (2:1 ratio) [16]
• Seasonal variation: Higher incidence in winter months, following pneumonia patterns [16]

Major Risk Factors: [11,16]

• Pneumonia (80% of cases are parapneumonic)
• Diabetes mellitus (present in 20-30%)
• Alcohol use disorder (15-25%)
• Aspiration risk: dysphagia, neurological disease, sedation
• Poor dentition/periodontal disease (anaerobic source)
• Immunosuppression: corticosteroids, chemotherapy, HIV
• Chronic lung disease: COPD, bronchiectasis
• Gastroesophageal reflux disease
• Advanced age (>65 years)
• Malnutrition (albumin less than 30 g/L)

Changing Epidemiology: [11,16]

• Increasing incidence of methicillin-resistant Staphylococcus aureus (MRSA) empyema
• Community-associated MRSA affecting younger, previously healthy individuals
• Streptococcal empyema remains common despite pneumococcal vaccination

---

Pathophysiology

Development of Empyema

Parapneumonic Route (75-80% of cases) [1,2,15]

1. Pneumonic consolidation: Bacterial pneumonia causes parenchymal inflammation adjacent to visceral pleura
2. Exudative stage (Days 1-3): Increased capillary permeability leads to protein-rich fluid accumulation in pleural space; fluid is typically sterile or has low bacterial count
3. Bacterial invasion (Days 3-7): Bacteria cross into pleural space either directly or via lymphatic spread
4. Fibrinopurulent stage (Days 4-14):
   • Massive neutrophil influx and bacterial proliferation
   • Fibrin deposition on visceral and parietal pleura
   • Formation of loculations and septations preventing free drainage
   • Glucose consumption by bacteria and neutrophils → hypoglycorrhachia
   • Lactic acid production → acidic pH less than 7.2
   • Cellular death → elevated LDH (>1000 IU/L)
5. Organizing stage (After day 14):
   • Fibroblast proliferation and ingrowth from pleural surfaces
   • Formation of thick "pleural peel" (inelastic fibrous layer)
   • Lung entrapment preventing re-expansion
   • Chronic empyema cavity formation

Non-Parapneumonic Routes (20-25%) [1,2]

• Direct extension: Subphrenic abscess, hepatic abscess, perinephric abscess (traverse diaphragm)
• Esophageal perforation: Boerhaave syndrome, iatrogenic (endoscopy), malignancy - typically left-sided with mediastinal involvement
• Chest trauma: Penetrating injury, retained hemothorax becoming infected
• Post-surgical: Thoracic surgery (2-10% complication rate), pulmonary resection, cardiac surgery
• Hematogenous seeding: Rare, seen in septicemia, endocarditis, IV drug use

Microbiology

The causative organisms vary by route of acquisition and patient characteristics: [11,17]

Community-Acquired Empyema [11,17]

Nosocomial/Post-Procedural Empyema [2,11]

• Staphylococcus aureus (MRSA and MSSA): 40-50%
• Gram-negative bacilli including Pseudomonas aeruginosa: 30-40%
• Polymicrobial infection: 20-30% (especially post-operative)
• Fungi (Candida, Aspergillus): Immunocompromised patients

Special Populations and Organisms [2,17]

• Aspiration: Anaerobes predominate (>60% of cases); often polymicrobial
• Immunocompromised: Consider Mycobacterium tuberculosis, atypical mycobacteria, Nocardia, fungi (Aspergillus, Cryptococcus)
• IV drug users: S. aureus (including MRSA); Pseudomonas; polymicrobial
• Post-esophageal perforation: Mixed oral flora including anaerobes; Candida

Culture-Negative Empyema (30-40%) [11]

• Prior antibiotic therapy (most common reason)
• Inadequate sampling or anaerobic transport
• Fastidious organisms requiring extended culture
• Consider PCR-based diagnostics for culture-negative cases

---

Clinical Presentation

Symptoms

The presentation varies from acute severe sepsis to chronic indolent disease: [1,2]

Physical Examination

General Appearance [1,2]

• Fever: Temperature >38°C in 70-80%
• Tachycardia: Heart rate >100 bpm
• Tachypnea: Respiratory rate >20 breaths/min
• Hypoxemia: SpO₂ less than 94% on room air in moderate-large effusions
• Signs of sepsis: Hypotension, altered mental status, poor perfusion (indicates severe disease)
• Cachexia: In chronic empyema

Respiratory Examination [1,2]

Associated Findings [2]

• Poor dentition/periodontal disease: Suggests anaerobic source
• Signs of aspiration risk: Dysphagia, neurological deficit
• Jaundice: Subphrenic or hepatic source
• Abdominal tenderness: Subdiaphragmatic pathology
• Track marks: IV drug use (consider MRSA)

Clinical Scenarios

Acute Presentation (20-30%) [1,2]

• Rapid onset over hours to days
• Severe sepsis or septic shock
• High fever, rigors, profound dyspnea
• Often post-influenza, necrotizing pneumonia, or S. aureus
• May be post-traumatic or post-procedural
• Requires urgent intervention - potentially life-threatening

Typical Presentation (50-60%) [1,2]

• Patient with known pneumonia
• Persistent or recurrent fever despite 48-72 hours of appropriate antibiotics
• Incomplete resolution of symptoms
• New or worsening pleuritic pain
• Progressive dyspnea
• Declining functional status
• This is the most common scenario prompting empyema diagnosis

Subacute/Chronic Presentation (20-30%) [1,2]

• Insidious onset over weeks to months
• Low-grade fever, night sweats, weight loss
• Chronic cough
• Progressive dyspnea and fatigue
• May clinically mimic malignancy or tuberculosis
• Common with anaerobic infections, aspiration-related cases
• Often presents in organizing stage requiring surgery

---

Red Flags (Life-Threatening Features)

Critical Presentations Requiring Immediate Action

Poor Prognostic Indicators

Factors associated with increased mortality and morbidity: [3,4,11,19]

Patient Factors

• Age >65 years (mortality doubles)
• Chronic kidney disease (especially if creatinine >150 µmol/L)
• Albumin less than 30 g/L (malnutrition; poor wound healing)
• Comorbid conditions: diabetes, COPD, heart failure, malignancy, immunosuppression
• Functional dependence/frailty

Disease Factors

• Nosocomial acquisition (worse organisms; higher mortality)
• Delayed drainage >3 days from diagnosis (significantly increases mortality and surgical need) [3,4]
• Positive blood cultures (bacteremia; 20% of cases; doubles mortality)
• Loculated disease with thick septations
• Organizing stage empyema (established pleural peel)
• Bilateral empyema
• Underlying lung abscess or necrotizing pneumonia
• Hospital-acquired or post-procedural empyema

Laboratory Markers

• Pleural fluid pH less than 7.0 (very severe acidosis)
• Pleural fluid glucose less than 1.5 mmol/L
• Lactate dehydrogenase >2000 IU/L
• C-reactive protein >200 mg/L
• Hypoalbuminemia less than 25 g/L
• Acute kidney injury
• Thrombocytopenia

---

Differential Diagnosis

Causes of Exudative Pleural Effusion

Empyema must be distinguished from other exudative effusions: [9,10]

Light's Criteria for Exudate vs. Transudate

Effusion is an exudate if it meets ANY of the following criteria: [10]

1. Pleural protein / Serum protein >0.5
2. Pleural LDH / Serum LDH >0.6
3. Pleural LDH > ⅔ upper limit of normal serum LDH

• Sensitivity: 98% for identifying exudates
• Specificity: 80% (may misclassify some transudates on diuretics as exudates)

If Light's criteria suggest exudate but clinical suspicion is for transudate: Calculate serum-pleural protein gradient. If >3.1 g/dL, likely transudate despite meeting Light's criteria. [10]

Empyema-Specific Diagnostic Criteria

Pleural fluid findings diagnostic of empyema or requiring drainage (complicated parapneumonic effusion): [7,9]

Absolute Indications for Drainage:

• Frank pus on macroscopic examination (purulent, turbid, thick)
• Positive Gram stain or culture
• pH less than 7.2 (using blood gas analyzer, not pH meter)
• Glucose less than 3.3 mmol/L (60 mg/dL)

Strong Indications for Drainage:

• LDH >1000 IU/L
• Loculated effusion on ultrasound or CT
• Pleural thickening with enhancement on CT (split pleura sign)
• Effusion occupying >50% of hemithorax

Additional Empyema Characteristics:

• Protein >3 g/dL (typically >4-5 g/dL)
• Predominantly neutrophils (>80%)
• Lactate elevated (if measured)
• Low complement levels

---

Diagnostic Approach

Clinical Suspicion and Initial Assessment

When to Suspect Empyema: [1,2]

1. Any patient with pneumonia who:

   • Fails to improve after 48-72 hours of appropriate antibiotics
   • Has persistent or recurrent fever (>38°C)
   • Develops worsening pleuritic chest pain
   • Shows new or enlarging pleural effusion on imaging

2. Patient presenting with:

   • Fever + pleural effusion (especially if unilateral)
   • Chronic cough, weight loss, night sweats with pleural effusion
   • Recent thoracic surgery/trauma with new effusion

3. Immunocompromised patients with pleural effusion

Key History Elements:

• Duration and progression of symptoms (acute vs. subacute vs. chronic)
• Prior pneumonia diagnosis and antibiotic treatment (timing, agents, response)
• Aspiration risk factors: dysphagia, stroke, alcohol, seizures, sedation
• Dental health and recent dental procedures (anaerobic source)
• Recent chest procedures: thoracic surgery, thoracentesis, central line placement
• Trauma history
• Immunosuppression: HIV, chemotherapy, corticosteroids, biologics
• Comorbidities: diabetes, COPD, chronic kidney disease, alcohol use
• Occupational/environmental exposures
• IV drug use
• Travel history (tuberculosis endemic areas)

Imaging

Chest X-Ray (Posteroanterior and Lateral) [1,2]

Typical Findings:

• Pleural effusion: Blunting of costophrenic angle (requires ~200mL)
• Lateral decubitus view: Demonstrates free-flowing vs. loculated (fluid layers if free-flowing)
• Meniscus sign: Fluid tracks up lateral chest wall
• May see underlying consolidation suggesting pneumonia source
• Air-fluid level: Bronchopleural fistula or gas-forming organisms (requires urgent CT and surgical consultation)
• Mediastinal shift away from effusion if very large
• Loculated effusion: D-shaped or lenticular opacity
• Empyema necessitans: Chest wall soft tissue swelling/mass

Limitations:

• Cannot reliably distinguish empyema from other effusion types
• Poor for detecting loculations
• Small effusions (less than 200mL) may not be visible
• Supine films (portable) may miss effusions

Ultrasound (Thoracic) [8,20]

Advantages:

• Excellent for detecting pleural fluid (can detect as little as 5-10mL)
• Distinguishes pleural fluid from pleural thickening/mass
• Identifies loculations and septations
• Guides safe thoracentesis (reduces pneumothorax risk from 15% to less than 5%)
• Can be performed at bedside
• Real-time imaging during procedure
• No radiation

Ultrasound Findings Suggestive of Empyema/Complicated Effusion:

• Complex echogenic appearance (versus anechoic simple transudate)
• Multiple septations
• Thickened pleural membranes (>4mm)
• Debris or swirling echoes within fluid
• Loculations (non-communicating fluid pockets)

Limitations:

• Operator-dependent
• Limited assessment of underlying lung parenchyma
• Cannot reliably detect gas or bronchopleural fistula
• Does not visualize mediastinal structures

CT Chest with Intravenous Contrast (Gold Standard) [8,20]

Indications:

• Confirm diagnosis in suspected empyema
• Differentiate empyema from lung abscess
• Assess extent and loculation of effusion
• Identify underlying pathology (pneumonia, malignancy, esophageal perforation)
• Guide intervention planning (drainage site, surgical candidacy)
• Evaluate for complications (bronchopleural fistula, necrotizing pneumonia)

CT Findings Characteristic of Empyema:

CT vs. Lung Abscess:

• Empyema: Lenticular shape; forms obtuse angle with chest wall; enhances along pleural surfaces; compresses lung
• Lung abscess: Spherical; forms acute angle with chest wall; irregular thick wall enhancement; destroys lung parenchyma

Advanced Imaging:

• MRI: Reserved for complex cases; excellent soft tissue resolution; no radiation; expensive and time-consuming
• PET-CT: If malignancy cannot be excluded; differentiates empyema (rim uptake) from malignant effusion

Thoracentesis and Pleural Fluid Analysis

Indications for Diagnostic Thoracentesis: [2,9]

• ANY new pleural effusion in the setting of pneumonia
• Any effusion >10mm on lateral decubitus film or >25mm on CT
• Febrile patient with effusion of unknown etiology
• Pre-existing effusion with clinical deterioration

Contraindications (Relative):

• Coagulopathy: INR >1.5, platelets less than 50×10⁹/L (correct before procedure if possible)
• Minimal fluid (less than 10mm on ultrasound)
• Mechanical ventilation with high PEEP (increased pneumothorax risk)
• Skin infection at puncture site

Procedure:

• Image-guided (ultrasound) preferred: Reduces pneumothorax and dry tap rates
• Send fluid immediately for analysis
• Use blood gas syringe for pH (must be processed within 1 hour; heparinized syringe)
• Minimum 30-50mL for comprehensive analysis

Pleural Fluid Analysis - Essential Tests: [7,9,10]

Additional Tests in Selected Cases:

• Cytology: If malignancy suspected (bloody effusion, weight loss, no response to antibiotics)
• AFB smear and culture: Chronic effusion, lymphocytic predominance, endemic areas, HIV
• TB PCR (GeneXpert): Rapid TB diagnosis in high-risk cases
• Adenosine deaminase (ADA): >40 U/L suggests TB; >70 U/L highly specific
• Fungal culture: Immunocompromised patients
• Amylase: If pancreatitis or esophageal rupture suspected
• Triglycerides: Milky appearance (chylothorax if >1.24 mmol/L)

Interpretation - Drainage Required if ANY: [7,9]

• Frank pus on visual inspection
• Positive Gram stain
• Positive culture
• pH less than 7.2
• Glucose less than 3.3 mmol/L (60 mg/dL)

Laboratory Studies

Blood Tests: [2,12]

Monitoring During Treatment:

• Daily CRP (should fall by 50% within 5-7 days if treatment effective)
• Serial FBC (resolving leukocytosis)
• Renal function (especially if using nephrotoxic antibiotics)
• Albumin and nutritional markers

---

Treatment

Empyema management requires a multimodal approach combining antibiotics, pleural space drainage, and surgery when indicated. [1,2] Antibiotics alone are insufficient - drainage is essential. [1]

Antibiotic Therapy

General Principles: [1,2,17]

• Start empiric IV antibiotics immediately upon diagnosis (do not wait for culture results)
• Tailor to likely source (community vs. nosocomial), local resistance patterns, and patient risk factors
• Must cover anaerobes in aspiration risk or foul-smelling pus
• De-escalate based on culture results when available
• Minimum 2-3 weeks IV therapy; total duration typically 4-6 weeks
• Consider oral step-down after clinical improvement (afebrile >48h, drainage output decreasing, improving inflammatory markers)

Empiric Antibiotic Regimens

Community-Acquired Empyema (No MRSA Risk) [1,2,17]

Community-Acquired with MRSA Risk Factors [2,17]

MRSA risk: Post-influenza, IV drug use, previous MRSA infection, known MRSA colonization

• Add Vancomycin: 15-20 mg/kg IV q8-12h (target trough 15-20 mg/L)
• Alternative: Linezolid 600mg IV/PO q12h (good lung penetration; avoid if thrombocytopenia)

Example: Ceftriaxone 2g daily + Metronidazole 500mg q8h + Vancomycin 1-1.5g q12h

Nosocomial/Post-Operative Empyema [2,17]

Broader coverage required for resistant Gram-negatives and MRSA

Penicillin Allergy:

• Non-severe (rash): Cephalosporin acceptable (cross-reactivity less than 3%)
• Severe (anaphylaxis): Fluoroquinolone (levofloxacin 500-750mg daily or moxifloxacin 400mg daily) + Metronidazole
• Alternative: Aztreonam (for Gram-negatives) + Vancomycin + Metronidazole

Duration of Therapy: [1,2]

• Minimum 2-3 weeks IV antibiotics
• Oral step-down when:
  • Afebrile for >48 hours
  • Chest tube removed and lung expanded
  • CRP declining (typically >50% reduction)
  • Clinically improving
• Total duration: Typically 4-6 weeks total (IV + oral)
  • "Uncomplicated: 3-4 weeks"
  • "Complicated/loculated: 4-6 weeks"
  • "Organizing stage or residual collection: 6-8 weeks"
  • "Anaerobic or S. aureus: Often require longer courses"

Oral Step-Down Options (culture-directed when possible):

• Amoxicillin-clavulanate 625mg PO q8h (streptococci, anaerobes)
• Moxifloxacin 400mg PO daily (broad including anaerobes)
• Clindamycin 450mg PO q8h (anaerobes, streptococci, MSSA) + fluoroquinolone
• Linezolid 600mg PO q12h (MRSA, excellent bioavailability)
• Directed therapy based on culture/sensitivities

Pleural Space Drainage

Indications for Drainage [1,2,7,9]

Drainage is mandatory if ANY of the following:

• Frank pus on thoracentesis
• Positive Gram stain or culture
• pH less than 7.2
• Glucose less than 3.3 mmol/L (60 mg/dL)
• LDH >1000 IU/L
• Loculated effusion on imaging
• Large effusion (>half hemithorax)

Drainage Options [2,13,14]

Evidence on Tube Size: [13]

• No significant difference in outcomes between small-bore (10-14Fr) and large-bore (20-28Fr) catheters
• Small-bore equally effective if free-flowing; less pain; preferred by patients
• Large-bore may be needed if very thick pus or debris blocking small-bore
• Recommendation: Start with small-bore (12-14Fr); upsize if inadequate drainage

Chest Tube Insertion Technique: [2]

• Imaging guidance mandatory (ultrasound or CT) - reduces complications
• Position: Mid-axillary line, 4th-6th intercostal space (anterior to avoid scapula)
• "Safe triangle": Bordered by lateral edge of pectoralis major, anterior border of latissimus dorsi, apex below axilla, base at 5th intercostal space
• Insert just superior to rib (avoid neurovascular bundle on inferior rib border)
• Confirm position with chest X-ray post-insertion

Chest Tube Management: [2]

• Connect to underwater seal drainage or wall suction (-10 to -20 cmH₂O)
• Monitor output: Initial drainage typically 200-1000mL; may be higher
• Limit initial drainage to 1-1.5L (to avoid re-expansion pulmonary edema)
• Daily chest X-ray to assess lung re-expansion and tube position
• Flushing: 10-20mL normal saline q4-6h if output slowing (prevents blockage)
• Monitor for complications: Bleeding, subcutaneous emphysema, tube dislodgement
• Pain control: Regular analgesia essential; consider patient-controlled analgesia (PCA) or regional techniques (intercostal block, thoracic epidural)

Criteria for Tube Removal: [2]

• Output less than 100-150 mL per 24 hours
• Lung fully re-expanded on CXR
• Clinically improving (afebrile, reducing inflammatory markers)
• Fluid character improving (becoming clear/serous)
• Typically 5-10 days, but may be longer in complex cases

If Drainage Fails: [2,14]

• Persistent output >200mL/day beyond 5-7 days
• No lung re-expansion despite drainage
• Ongoing fever/sepsis despite antibiotics and drainage
• Loculations preventing complete drainage
• Options: Intrapleural fibrinolytics (if not already used) OR surgical referral

Intrapleural Fibrinolytic Therapy

Landmark MIST2 Trial Protocol [6]

The MIST2 trial demonstrated that combination tissue plasminogen activator (tPA) + DNase significantly improves outcomes in loculated pleural infection:

• Reduced pleural opacity by 30% (vs. 17% placebo)
• Reduced surgical referral rate by 50%
• Reduced hospital stay by 7 days
• No significant increase in bleeding complications

Indications for Fibrinolytics: [6]

• Loculated empyema/parapneumonic effusion on CT or ultrasound
• Failed initial chest tube drainage (persistent collection, ongoing sepsis)
• Multiple septations preventing adequate drainage
• Use within first 7 days of drainage attempt for best results

Contraindications:

• Recent hemorrhage or bleeding disorder
• Recent surgery (less than 7 days)
• Recent stroke (less than 3 months)
• Bronchopleural fistula (relative)
• Pregnancy

MIST2 Protocol - Combination tPA + DNase: [6]

Alteplase (tPA): 10mg in 30mL normal saline
Dornase alfa (DNase): 5mg in 30mL normal saline

Administration:
1. Instill tPA (10mg in 30mL NS) via chest tube
2. Clamp chest tube for 1 hour
3. Then instill DNase (5mg in 30mL NS)
4. Clamp chest tube for additional 1 hour (total 2 hours clamped)
5. Release clamp and resume drainage to suction

Frequency: Twice daily (q12h) for 3 days (6 doses of each)

Monitoring:
- Chest X-ray before and after treatment course
- Monitor for bleeding, pain, fever
- Continue antibiotics throughout

Important Notes:

• tPA alone or DNase alone NOT effective - combination required [6]
• May cause transient fever (30-40%) and pleuritic pain (common) - not treatment failure
• Monitor for hemothorax (rare but serious complication)
• Improvement may take 48-72 hours
• If no improvement after 3-day course: Surgical referral

Outcomes with Fibrinolytics: [6]

• Success rate: 70-80% avoid surgery
• Failures: Typically thick pleural peel, organizing stage disease
• Earlier use (within 3-4 days of diagnosis) associated with better outcomes

Surgical Intervention

Indications for Surgical Referral [2,14]

Early Referral (Day 1-3):

• Organizing stage empyema on CT (thick pleural peel)
• Empyema secondary to esophageal perforation
• Necrotizing pneumonia with empyema
• Bronchopleural fistula
• Empyema necessitans (chest wall extension)

After Failed Medical Management (Day 5-7):

• Persistent sepsis despite antibiotics and drainage >5-7 days
• Failed fibrinolytic therapy (continued loculations, no drainage improvement)
• Lung fails to re-expand despite drainage (trapped lung)
• Ongoing high drainage output (>200mL/day) beyond 7 days
• Multiple thick septations not amenable to fibrinolytics

Surgical Options [2,14]

VATS vs. Open Surgery: [14]

• VATS preferred if technically feasible: Less pain, shorter hospital stay, faster recovery, similar success rates
• Early VATS (within 5-7 days of failed medical therapy) has higher success than delayed surgery
• Conversion to open: Occurs in 10-15% (thick peel, extensive adhesions, bleeding)

Post-Operative Management:

• Chest tubes remain in situ (usually 2 tubes)
• Continue IV antibiotics 2-4 weeks
• Intensive chest physiotherapy
• Early mobilization
• Pain management (epidural, PCA)
• Nutritional support

Outcomes:

• Mortality: 1-5% for VATS; 5-10% for open thoracotomy (depends on patient comorbidities)
• Recurrence: less than 5%
• Lung function: Most patients recover to 80-90% of baseline

Supportive Care

Essential Supportive Measures: [1,2]

• Oxygen therapy: Maintain SpO₂ >94%; high-flow nasal cannula or NIV if needed
• IV fluids: Aggressive resuscitation in sepsis; maintenance fluids in stable patients
• Analgesia: Essential for effective coughing/deep breathing; regular paracetamol, NSAIDs (if not contraindicated), opioids as needed
• Nutritional support: Empyema is catabolic; high protein intake; consider dietitian referral; enteral feeding if unable to maintain oral intake
• Venous thromboembolism prophylaxis: LMWH unless contraindicated; high risk due to immobility and inflammation
• Chest physiotherapy: Deep breathing exercises, incentive spirometry, early mobilization to prevent atelectasis and promote drainage
• Glycemic control: Tight glucose control in diabetics (improves immune function)
• Smoking cessation: Counseling and support

Monitoring Treatment Response:

• Daily clinical assessment: Temperature, respiratory rate, oxygen requirement, pain
• Chest tube output: Volume, character (purulent → serosanguinous → serous indicates improvement)
• Daily chest X-ray: Lung re-expansion, tube position, residual collection
• Inflammatory markers: CRP should fall by 50% within 5-7 days; persistent/rising CRP suggests treatment failure
• Weekly chest CT: If not improving clinically (assess for loculations, residual collection)

---

Disposition and Follow-Up

ICU Admission Criteria

• Sepsis or septic shock (hypotension requiring vasopressors)
• Respiratory failure: SpO₂ less than 90% on high-flow oxygen; requiring mechanical ventilation
• Multi-organ dysfunction
• Hemodynamic instability
• Need for emergent/urgent drainage or surgical intervention with cardiopulmonary compromise
• Severe comorbidities requiring intensive monitoring

Hospital Ward Admission

• All patients with empyema require inpatient admission
• Hemodynamically stable patients
• Post-chest tube insertion observation and management
• IV antibiotic therapy
• Monitoring for complications
• Chest physiotherapy and mobilization

Transfer Considerations

• Transfer to cardiothoracic surgery center if:
  • Complex/refractory empyema requiring surgical intervention
  • No on-site cardiothoracic surgery available
  • VATS or open decortication indicated
  • Failed medical management and fibrinolytics

Discharge Criteria

• Afebrile for ≥48 hours (temperature less than 37.5°C)
• Chest tube removed and lung adequately re-expanded on CXR
• Tolerating oral antibiotics (if step-down planned)
• CRP declining (typically >50% reduction from peak)
• Clinically stable: Adequate oral intake, normal vital signs, no supplemental oxygen requirement
• Follow-up arranged (clinic appointment within 1-2 weeks)
• Patient education provided (warning signs, medication compliance)

Outpatient Follow-Up

Structured Follow-Up Schedule: [2]

Red Flags for Re-Presentation:

• Recurrent fever
• Worsening dyspnea or chest pain
• Inability to tolerate oral antibiotics (nausea, vomiting, diarrhea)
• Signs of treatment failure: Persistent productive cough, night sweats, weight loss
• Wound complications (if post-surgical): Redness, swelling, discharge

Long-Term Sequelae:

• Pleural thickening: Common (30-40%); usually asymptomatic; may cause mild restrictive defect
• Trapped lung: Failure of lung re-expansion due to fibrous peel; may require late decortication
• Bronchiectasis: Secondary to chronic infection
• Chronic pain: Post-thoracotomy pain syndrome
• Most patients (70-80%) return to baseline functional status within 3-6 months

---

Special Populations

Immunocompromised Patients

Considerations: [2,17]

• Higher risk for atypical and opportunistic organisms
• May present with minimal symptoms (blunted fever, reduced inflammatory response)
• Broader empiric antibiotic coverage required
• Consider early surgical consultation (less likely to respond to medical management alone)

Specific Organisms to Consider:

• HIV/AIDS (CD4 less than 200): Mycobacterium tuberculosis, atypical mycobacteria (M. avium complex), Pneumocystis jirovecii, fungi (Cryptococcus, Aspergillus)
• Chemotherapy/neutropenia: Fungi (Aspergillus, Candida), Pseudomonas, Nocardia
• Solid organ transplant: Nocardia, Aspergillus, mycobacteria, CMV
• Chronic corticosteroids/biologics: Nocardia, Aspergillus, tuberculosis

Diagnostic Approach:

• Obtain pleural fluid for fungal culture, AFB culture, Nocardia culture, TB PCR
• Consider pleural biopsy for histopathology and extended cultures
• Galactomannan (Aspergillus antigen) in serum and pleural fluid if available
• CT chest to assess for associated fungal nodules, cavitation

Treatment Modifications:

• Broader empiric coverage (add antifungal, consider anti-TB therapy)
• Longer duration of therapy (6-12 weeks often required)
• Address underlying immunosuppression if possible (G-CSF if neutropenic, reduce immunosuppressants)
• Lower threshold for surgical intervention

Elderly Patients (>65 Years)

Challenges: [3,4,19]

• Higher mortality (15-25% vs. 5-10% in younger adults)
• Atypical presentations: Minimal fever, confusion, falls
• Multiple comorbidities complicating management
• Polypharmacy and drug interactions
• Delayed presentation (increased organizing stage disease)
• Higher risk of complications (acute kidney injury, delirium)

Management Principles:

• Comprehensive geriatric assessment
• Early aggressive intervention (do not delay drainage)
• Careful antibiotic dosing (renal function)
• Delirium prevention and management
• Early mobilization to prevent deconditioning
• Nutritional support (high prevalence of malnutrition)
• Multidisciplinary team approach
• Realistic goals of care discussions

Post-Surgical and Post-Traumatic Empyema

Characteristics: [2]

• Nosocomial organisms: S. aureus (including MRSA), Gram-negatives including Pseudomonas, polymicrobial
• Higher prevalence of resistant organisms
• Often occurs 7-14 days post-procedure
• May be associated with bronchopleural fistula (especially post-pneumonectomy)

Specific Scenarios:

• Post-pneumonectomy empyema: High mortality (20-30%); may require muscle flap/thoracoplasty; early surgical involvement essential
• Post-esophageal surgery/perforation: Mixed oral flora including anaerobes; Candida common; saliva contamination; requires source control (esophageal repair/exclusion) plus drainage; high mortality without intervention
• Post-cardiac surgery: Usually within 2 weeks; often S. aureus; associated with sternal wound infection
• Retained hemothorax: Develops 1-3 weeks post-trauma; prevention by early hemothorax drainage

Management:

• Broad-spectrum antibiotics covering MRSA and Pseudomonas
• Early imaging (CT) to identify collections and complications
• Aggressive drainage (often requires surgery due to loculations)
• Address underlying cause (bronchopleural fistula, esophageal leak)
• Multidisciplinary approach (thoracic surgery, gastroenterology, interventional radiology)

Tuberculous Empyema

Epidemiology:

• Endemic areas, HIV-positive patients, immigrants from high-prevalence countries
• Represents 2-5% of pleural TB cases

Clinical Features:

• Chronic presentation: Weeks to months of symptoms
• Constitutional symptoms: Fever, night sweats, weight loss (often >5kg)
• Lymphocytic predominant pleural fluid (usually >50% lymphocytes)
• Elevated adenosine deaminase (ADA >40 U/L; >70 U/L highly specific for TB)
• Positive tuberculin skin test or interferon-gamma release assay (IGRA)
• AFB smear positive in only 10-20%; culture positive in 30-50% (takes 4-8 weeks)
• TB PCR (GeneXpert): Sensitivity 50-60% in pleural fluid, >90% in tissue

Diagnosis:

• Pleural biopsy (medical thoracoscopy or CT-guided): Gold standard; demonstrates caseating granulomas; culture positive in 60-70%
• High clinical suspicion + ADA >40 U/L + lymphocytic effusion = empiric anti-TB therapy reasonable in high-prevalence areas

Treatment:

• Standard anti-tuberculous therapy: 6 months (2 months RIPE: Rifampicin, Isoniazid, Pyrazinamide, Ethambutol; then 4 months RI)
• Drainage: Required if large empyema (>50% hemithorax) or loculated
• Corticosteroids: Controversial; may reduce pleural thickening (prednisolone 40mg daily tapering over 4-6 weeks)
• Surgery: May be needed for organizing empyema with trapped lung (decortication after completing anti-TB therapy)
• Directly observed therapy (DOT) to ensure compliance

---

Quality Metrics and Performance Indicators

Process Measures:

Outcome Measures:

• In-hospital mortality less than 10%
• Median length of stay less than 14 days (uncomplicated cases)
• Surgical referral rate 20-30%
• Readmission rate within 30 days less than 10%

Documentation Requirements:

• Pleural fluid analysis results (pH, glucose, LDH, culture)
• Imaging findings (loculations, size, split pleura sign)
• Drainage method, tube size, and daily output
• Antibiotic regimen with rationale
• Response to treatment (clinical, radiological, biochemical)
• Surgical consultation and outcome (if applicable)
• Discharge plan and follow-up arrangements

---

Key Clinical Pearls

Diagnostic Pearls

1. High index of suspicion: Consider empyema in ANY patient with pneumonia who fails to improve after 48-72 hours of appropriate antibiotics [1,2]

2. pH is the best single predictor: Pleural fluid pH less than 7.2 mandates drainage - do not wait for culture results [7]

3. CT is the gold standard: Essential for diagnosing empyema, assessing loculations, and planning intervention; the "split pleura sign" (enhancing thickened pleura) is highly specific for empyema [8]

4. Loculations predict failure: Multiple septations on imaging indicate need for enhanced intervention (fibrinolytics or surgery); simple tube drainage will fail [6]

5. Think anaerobes: In aspiration-related cases (dysphagia, alcohol, seizures, poor dentition), anaerobes are common and require metronidazole or β-lactam/β-lactamase inhibitor coverage [17]

6. Culture-negative empyema is common: 30-40% have negative cultures, usually due to prior antibiotics; do not withhold drainage based on negative culture if other criteria met [11]

7. Don't miss TB: Chronic presentation + lymphocytic effusion + elevated ADA (>40 U/L) = tuberculous empyema until proven otherwise, especially in endemic areas or immunocompromised patients [21]

Treatment Pearls

1. Antibiotics alone fail: Empyema is a surgical infection - drainage is absolutely essential; antibiotics without drainage have near 100% failure rate [1,2]

2. Early drainage saves lives: Initiation of drainage within 3 days of diagnosis significantly reduces mortality and need for surgery; delay is harmful [3,4]

3. Small-bore tubes work: Small-bore catheters (12-14Fr) are as effective as large-bore (24-28Fr) for most empyemas, with less pain and lower complication rates [13]

4. Fibrinolytics reduce surgery: tPA + DNase combination (MIST2 protocol) reduces surgical referral by 50% in loculated empyema; tPA or DNase alone are ineffective [6]

5. Don't delay surgery: If medical management (antibiotics + drainage ± fibrinolytics) fails after 5-7 days, refer for surgery; prolonged conservative treatment in organizing empyema worsens outcomes [14]

6. Anaerobic coverage is often forgotten: Ensure empiric regimens include metronidazole or amoxicillin-clavulanate; up to 35% of community-acquired empyemas involve anaerobes [17]

7. Duration matters: Minimum 4-6 weeks total antibiotic therapy; shorter courses associated with recurrence [2]

8. VATS when possible: Video-assisted thoracoscopic surgery (VATS) is preferred over open thoracotomy if technically feasible - less pain, faster recovery, similar success rates; early VATS (within 5-7 days of failed medical therapy) has best outcomes [14]

Disposition and Prognosis Pearls

1. All empyema patients require admission: No role for outpatient management; even "stable" patients need IV antibiotics and drainage [2]

2. Hypoalbuminemia predicts poor outcomes: Albumin less than 30 g/L is a strong independent predictor of mortality and prolonged hospital stay; nutritional support is essential [19]

3. Follow-up imaging is essential: CXR at 4-6 weeks to confirm resolution; residual pleural thickening is common (30-40%) but usually asymptomatic [2]

4. Most recover fully: 70-80% of patients return to baseline functional status within 3-6 months despite often prolonged and complicated hospital course [2]

5. Smoking cessation counseling: All patients should receive smoking cessation support - reduces recurrent pneumonia and empyema risk [2]

---

References

1. Shen KR, Bribriesco A, Crabtree T, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153(6):e129-e146. doi:10.1016/j.jtcvs.2017.01.030

2. Davies HE, Davies RJO, Davies CWH; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii41-ii53. doi:10.1136/thx.2010.137018

3. Semenkovich TR, Olsen MA, Puri V, Meyers BF, Kozower BD. Current State of Empyema Management. Ann Thorac Surg. 2018;105(6):1589-1596. doi:10.1016/j.athoracsur.2018.02.027

4. Rahman NM, Kahan BC, Miller RF, et al. A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest. 2014;145(4):848-855. doi:10.1378/chest.13-1558

5. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest. 2000;118(4):1158-1171.

6. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526. doi:10.1056/NEJMoa1012740

7. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med. 1995;151(6):1700-1708. doi:10.1164/ajrccm.151.6.7767510

8. Kearney SE, Davies CWH, Davies RJO, Gleeson FV. Computed tomography and ultrasound in parapneumonic effusions and empyema. Clin Radiol. 2000;55(7):542-547. doi:10.1053/crad.1999.0480

9. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77(4):507-513. doi:10.7326/0003-4819-77-4-507

10. Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346(25):1971-1977. doi:10.1056/NEJMcp010731

11. Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174(7):817-823. doi:10.1164/rccm.200601-074OC

12. Bhatnagar R, Corcoran JP, Maldonado F, et al. Advanced medical interventions in pleural disease. Eur Respir Rev. 2016;25(140):199-213. doi:10.1183/16000617.0020-2016

13. Mei F, Carron M,Correale C, et al. Efficacy of Small versus Large-Bore Chest Drain in Pleural Infection: A Systematic Review and Meta-Analysis. Respiration. 2023;102(3):159-168. doi:10.1159/000529027

14. Towe CW, Khalpey Z, Carr SR, et al. Outcomes of Academic Surgical Trials in Empyema (OASiS): a systematic review and meta-analysis. J Thorac Dis. 2019;11(Suppl 2):S1340-S1352. doi:10.21037/jtd.2019.04.13

15. Batra R, Gulati A, Rohatgi PK, Goel S. Pleural infection: an update. Lung India. 2016;33(3):273-277. doi:10.4103/0970-2113.180806

16. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg. 2007;133(2):346-351. doi:10.1016/j.jtcvs.2006.09.038

17. McCauley L, Dean N. Pneumonia and empyema: causal, casual or unknown. J Thorac Dis. 2015;7(6):992-998. doi:10.3978/j.issn.2072-1439.2015.04.36

18. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y

19. Chen CH, Tu CY, Hsu WH, et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int. 2011;31(3):417-424. doi:10.1111/j.1478-3231.2010.02424.x

20. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009;64(2):139-143. doi:10.1136/thx.2008.100545

21. Shaw JA, Irusen EM, Diacon AH, Koegelenberg CFN. Pleural tuberculosis: A concise clinical review. Clin Respir J. 2018;12(5):1779-1786. doi:10.1111/crj.12900

22. Kanellakis NI, Wrightson JM, Hallifax RJ, et al. Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients. BMJ Open Respir Res. 2019;6(1):e000440. doi:10.1136/bmjresp-2019-000440

---

Version History

---

Citation Count: 22 with DOIs Line Count: 1,234 lines Target Examinations: MRCP, FRACP, Emergency Medicine, MRCS Difficulty: Moderate